News

BrightSpec Announces $18.4 Million Financing Round Led by Genoa Ventures and Arboretum Ventures

CHARLOTTESVILLE, Va., /PRNewswire/ — BrightSpec, Inc., a life science tools company commercializing Molecular Rotational Resonance (MRR) spectroscopy, announced today the closing of an $18.4 million Series C financing round, led by Genoa Ventures and Arboretum Ventures. The round includes participation from existing investors including Medvest Capital, Felton Group LLC, and the UVA Seed Fund.  Jenny Rooke, Ph.D., and Dan Kidle, from Genoa and Arboretum respectively, have joined BrightSpec’s Board of Directors.

“Genoa Ventures and Arboretum are both high-impact investment partners that we know will bring enormous value to our company with their expertise in building and supporting life science tools companies,” said Walter H. Colsman, CEO of BrightSpec. “We look forward to working with them as we move forward with commercializing our innovative hardware and software solutions for chemical structural elucidation and quantitation in essential  markets like pharmaceutical and industrial chemical manufacturing.”

BrightSpec is commercializing MRR, the first novel spectroscopic technique to commercialize in decades, to rapidly and definitively characterize the unique 3-dimensional structure of small molecules, including all forms of structural, spatial, and isotopic isomers. Traditional techniques, like NMR, FT-IR, and MS, often require purified reference standards, sample preparation, and extensive method development to resolve known isomers.  MRR does not require reference standards, sample preparation, or a priori knowledge of an isomer, reducing method development timelines from months to days.  These abilities make the technique ideal for rapid structural elucidation in high-value use cases like industrial chemical and pharmaceutical manufacturing.

MRR utilizes computational quantum chemistry to predict and validate a new structure, eliminating the need for any reference standards. BrightSpec offers an extensive database of calculated and validated structural spectra and tools for the rapid identification of unknown compounds in crude samples. High throughput analysis can be achieved without chromatography steps, providing quantitation directly out of a crude mixture in minutes.  Paired with software solutions and minimal sample prep, customers can deploy targeted instruments outside of the analytical lab for rapid, routine analysis.

“We have been impressed with the market validation the BrightSpec team has achieved in early customer testing during the development of their hardware and software solutions,” said Jenny Rooke, Ph.D., Founder and Managing Director of Genoa Ventures. “MRR has the potential to transform both the speed and precision at which molecules are characterized. We believe the team assembled at BrightSpec is uniquely positioned to bring MRR to market and make it the gold standard in structural elucidation.  The platform they are building has the opportunity to accelerate the development of new molecules, as well reduce costs in manufacturing and enhance quality control downstream.”

“Our investment in BrightSpec is based on their unique approach to solving the ubiquitous identification challenges in analytical chemistry,” said Dan Kidle, Managing Partner at Arboretum Ventures. “BrightSpec is harnessing modern computational tools that bring digital precision, speed, and confidence to classical analytical chemistry techniques.”

For more information, visit www.brightspec.com.

Recent News

05/20/2024

Governor Youngkin Announces New VIPC-Led Initiative that Catalyzes and Attracts Investment into Virginia-based, Innovation-driven Startups and Entrepreneurs

Governor Glenn Youngkin announced a new initiative led by Virginia Innovation Partnership Corporation (VIPC) that expands investment and growth opportunities for Virginia-based, innovation-driven startups and entrepreneurial ecosystems throughout the Commonwealth. Leveraging previous Virginia-awarded federal funding from the U.S. Department of Treasury, under its SSBCI Equity/Venture Capital Program, VIPC’s Virginia Invests launches new investment partnerships with an

05/12/2024

Nanochon closes $4M Series Seed Prime

Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round. The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others. Nanochon intends to use the funds to

05/09/2024

Agrospheres Announces Major Commercial Development Agreement with FMC Corporation

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health, today announced the signing of a major collaboration with FMC Corporation (NYSE:FMC), a global leader in agriculture sciences. The long-term alliance represents a major milestone in launching AgroSpheres’ vertically integrated product pipeline. Powered by a recent $25M Series B funding round and construction